Business
Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogs Company strategy: In discussions with multiple potential animal health company partners to expand ...
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Canalevia® (crofelemer delayed-release tablets), under the name Canalevia®-CA1, is conditionally approved by the FDA for treatment of CID in dogs","length":161,"tagName":"p"},{"type":"text","content":"Company strategy: In discussions with multiple potential animal health company partners to expand the indication and commercialize Canalevia for treatment of general diarrhea globally","length":183,"tagName":"p"},{"type":"text","content":"Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs","length":248,"tagName":"p"},{"type":"text","content":"Enrollment has reached approximately 25% in Jaguar's ongoing field study of Canalevia-CA1 in dogs","length":101,"tagName":"p"},{"type":"text","content":"SAN FRANCISCO, CA / ACCESS Newswire / August 21, 2025 / Jaguar Health, Inc.(NASDAQ:JAGX) ("Jaguar"), under its Jaguar Animal Health tradename for the veterinary market, today announced it is participating in the 2025 Animal Health Summit in support of the company's goal of securing a collaboration to expand the indication of Canalevia (crofelemer delayed-release tablets) from treatment of chemotherapy-induced diarrhea (CID) in dogs to treatment of general diarrhea in dogs. Canalevia, under the name Canalevia-CA1, is conditionally approved by the U.S. Food and Drug Administration (FDA) for treatment of CID in dogs. The Animal Health Summit, hosted by KC Animal Health Corridor, takes place August 25-26, 2025 in Kansas City, Missouri.","length":755,"tagName":"p"},{"type":"text","content":""I'm pleased to report that Jaguar is currently in discussions with multiple potential animal health company partners regarding collaborating on the development, approval, and commercialization of Canalevia for treatment of general diarrhea in dogs," said Lisa Conte, Jaguar's Founder and CEO. "Specifically, our objective is to partner with an animal health company to achieve three parallel goals for Canalevia: Expand the U.S. indication from CID in dogs to treatment of general diarrhea in dogs; obtain approval in the European Union for Canalevia for treatment of general diarrhea in dogs based on existing Jaguar ...